Pediatric cancers often mimic fetal tissues and express proteins normally silenced
postnatally that could serve as immune targets. We developed T cells expressing chimeric …

Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed
poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated …

The reprogramming of a patient's immune system through genetic modification of the T cell
compartment with chimeric antigen receptors (CARs) has led to durable remissions in …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that
have turned the tables of conventional cancer treatments in certain hematologic …

High grade gliomas (HGG) comprise a heterogeneous group of brain malignancies with
dismal prognosis. Current standard-of-care includes radiation, chemotherapy, and surgical …

We generated MHC-independent chimeric antigen receptors (CARs) directed to the GD2
antigen expressed by neuroblastoma tumor cells and treated patients with this disease. Two …

Simple Summary Glioblastoma is the most common brain cancer, and prognosis remains
dismal. Continued efforts to find better treatments have shown the promise of …

Malignant brain tumors rank among the most challenging type of malignancies to manage.
The current treatment protocol commonly entails surgery followed by radiotherapy and/or …